Oryzon Genomics - Clinical ramp in Q3; several catalysts approaching
Oryzon Genomics reported Q322 results that are largely in line with our expectations. The clinical ramp up of its key assets, iadademstat and...
369 Views
Oryzon Genomics - Encouraging safety data in PORTICO
Oryzon Genomics has announced promising preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial at the 10th European...
806 Views
Oryzon Genomics - Preclinical collaboration in orphan disease
Oryzon Genomics has announced that it is has entered into a partnership with the Charcot-Marie-Tooth Research Foundation (CMTRF). The collaboration...
855 Views
Oryzon Genomics - Costs up but company remains well funded
Oryzon Genomics has reported results for H122 and highlighted the progress of key assets iadademstat and vafidemstat during the period. It reported...
747 Views
Oryzon Genomics - CRADA win to provide a halo effect
Oryzon has been awarded a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute (NCI) to develop its lead...
723 Views